# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Douglas Tsao reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $18 price target.
Preliminary results of AEON Biopharma's Phase 2 trial for chronic migraine treatment reveal no significant improvement over...